Navigation Links
California Stem Cell Agency Exaggerated Its Role in Funding Key Research
Date:4/16/2008

Agency Claimed State Funding Led to Important Clinical Trials

SANTA MONICA, Calif., April 16 /PRNewswire-USNewswire/ -- California's stem cell agency overstated and hyped the importance of its funding in enabling clinical trials for a drug to treat a severe blood disorder, Consumer Watchdog said today, seriously undercutting the agency's credibility and alienating those who support publicly funded stem cell research.

Last week the California Institute For Regenerative Medicine (CIRM) issued a news release titled "First Clinical Trial Begins for a Therapy Enabled By CIRM Funding." The announcement even drew a comment from Gov. Arnold Schwarzenegger, who issued a release saying CIRM funding led to the discovery. He added, "I am proud of our state's commitment to stem cell research, which delivers the best promise in finding treatments for deadly and debilitating diseases."

A report on today's California Stem Cell Report published by David Jensen makes clear how little CIRM funding was actually involved in the research by a team led by UCSD's Catriona Jamieson.

"There is important scientific work here that led quickly to an important clinical trial," said John M. Simpson, director of Consumer Watchdog's Stem Cell Project. "But the fact is that CIRM is jumping on the bandwagon claiming credit for contributions that were at best rather trivial."

The initial CIRM news release about the clinical trial said that Jamieson was funded by a stem cell SEED grant that was approved in February 2007. That grant was given to fund the derivation of cancer-causing stem cells from human embryonic stem cells. The research that led to the clinical trial did not involve human embryonic stem cells at all.

Moreover, according to the official notice of grant award, the time period for the CIRM funded grant of $613,305 was from Aug. 1, 2007- July 31, 2009. The university officially signed off on the grant on Aug. 31, 2007. The paper
'/>"/>

SOURCE Consumer Watchdog
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Northern California Foot and Ankle Center Santa Rosa Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Research Trial
2. New Conflict of Interest Violations Revealed at California Stem Cell Institute
3. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
4. Veto of Californias Condoms in Prisons Bill: "Politics Over Public Health," Says AHF
5. California Legislature Passes Historic HIV Testing Bill (AB 682); AHF Urges Governor to Sign Crucial Lifesaving Legislation
6. Saving Lives of California Residents Who Develop Skin Cancer Each Year: The Key is Early Detection and Treatment
7. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
8. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
9. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
10. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
11. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 According to Millennium Research ... market intelligence, health care reforms in China supported ... in 2009, and will continue to fuel growth ... Asia Pacific Markets for Interventional Cardiology Devices 2010 ... Chinese government will allow the Chinese drug-eluting stent ...
(Date:12/16/2009)... -- Biovista Inc.,today announced that it was awarded ... the 2009 New England Venture Summit, held on ... cutting edge private companies,driving the future of innovation, ... other privately held companies that play a leading ... Clean-tech sectors. , "We ...
(Date:12/16/2009)... -- BioSpecifics Technologies Corp. (Nasdaq: BSTC ), ... products, today announced top-line efficacy and safety results ... for the treatment of Peyronie,s disease. Peyronie,s disease ... on the shaft of the penis, which can ... or impossible in advanced cases. The Phase 2b ...
Breaking Medicine Technology:Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 2Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 3Biovista Inc. Named Top Innovator in Life Sciences 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 2BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 3BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronie's Disease 4No Link Found Between Birth Anesthesia and Learning Issues 53665 1No Link Found Between Birth Anesthesia and Learning Issues 53665 2Certain Arthritis Crohns Drugs May Raise Kids Cancer Risk 3A FDA 53660 1Certain Arthritis Crohns Drugs May Raise Kids Cancer Risk 3A FDA 53660 2Certain Arthritis Crohns Drugs May Raise Kids Cancer Risk 3A FDA 53660 3Silenced genes as a warning sign of blood cancer 53655 1Silenced genes as a warning sign of blood cancer 53655 2
... study evaluating DUROS(R) continuous delivery of exenatide for the ... Intarcia Therapeutics, Inc. today announced the completion of patient ... 650 (DUROS(R) continuous delivery of exenatide). The study is ... and involves the treatment of 44 patients with type ...
... Trial Expected to Initiate in 2010 for BlinatumomabNEW YORK, ... ), a biopharmaceutical company developing novel, proprietary antibodies for ... held an R&D Day for investors and financial analysts ... The presentations highlighted significant areas of development across Micromet,s ...
Other Medicine Technology:Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 2Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes 3Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 2Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 3Micromet Presents Update on BiTE Antibody Pipeline and Reviews Key AACR Presentations at R&D Day 4
(Date:12/16/2009)... Raises Significant Funds to Benefit of Children with Autism ... Taylor, Gary Cole and Zachary Levi Join Ben Stiller ... ANGELES, Dec. 16 At its 13th annual ... individuals. Hasbro President & CEO Brian ... in recognition of his far-reaching philanthropic leadership and commitment ...
(Date:12/16/2009)... -- Every year in the United States, 160,000 cases ... of the disease, making it the second leading cause ... , As researchers and clinicians fervently look for causes ... of studies producing more and more promising results ... genetics at Case Western Reserve University School of Medicine ...
(Date:12/16/2009)... Immucor, Inc. (Nasdaq: BLUD ), a global leader ... industry, today announced that Paul D. Mintz, M.D. has ... director, effective January 1, 2010. ,, Dr. Mintz ... for more than 30 years. He is a tenured ... Virginia School of Medicine. He also serves as director ...
(Date:12/16/2009)... Allscripts (Nasdaq: MDRX ) announced today that ... three and six months ended November 30, 2009 ... 11, 2010. Allscripts management will host a conference ... and other information at 8:30 AM Eastern Standard ... http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, Allscripts fiscal second quarter earnings ...
(Date:12/16/2009)... widely used human embryonic stem cell lines lack genetic ... must be addressed to ensure that all sectors of ... University of Michigan research team. ,, In the first ... 47 embryonic stem cell lines, including most of the ... determined the genetic ancestry of each line and found ...
Breaking Medicine News(10 mins):Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 2Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 4Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 5Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 2Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 3Health News:Immucor Appoints New Board Director 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5
... tumor disease has affected the ecological balance existing between native ... disease the number of devils has sharply reduced. David Pemberton ... the devil population in the Mt William National Park. ... see carcasses lying around the area. Wedge-tailed eagles are feeding ...
... research done by Dr Allan Pantuck it was found that ... , Prostate cancer is the most common cancer affecting men ... each year and about 10,000 die from the disease. ... presence of prostate cancer. But study shows that consumption of ...
... has revealed that having several older brothers increases the chances ... adds //weight to the idea of a biological basis for ... University in St Catharines, Canada said, "It's likely to be ... is probably a biological basis for homosexuality." ,S ...
... be associated with reduced length of antibiotic treatment for ... ,A biomarker of infection, procalcitonin appeared to ... therapy as compared with other parameters. ,The ... kind, appears in the first issue for July 2006 ...
... August, and Uganda will have one more problem to surmount ... stock of free antiretroviral//. Soon, Uganda will be left with ... grips of disease. ,The stock is said to ... ups will not have enough to tide over the next ...
... from Laval University, Quebec say that chronic job stress ... white-collar workers. // ,The research, appearing in the ... levels and tight deadlines increased blood pressure especially in ... seven years. "Our study supports the hypothesis that job ...
Other Medicine News:Health News:Procalcitonin-Guided Antibiotic Therapy Proved Effective in CAP Cure 2Health News:Procalcitonin-Guided Antibiotic Therapy Proved Effective in CAP Cure 3
Corning 7078 Calibrated"to deliver". multi-pack plugged capacity 5 mL...
... operative hysteroscopy, the surgeon and O.R. staff ... the dangers of fluid intravasation. Manual methods ... solution is the DOLPHIN II Fluid Management ... market leader in endoscopic irrigation. It has ...
... precision 4mL PYREX volumetric pipets ... Contain" (TC - bottom line) ... top line) to specifications for ... are color-coded with colored graduations ...
1000L...
Medicine Products: